Pharmacokinetic benefits of 3,4-dimethoxy substitution of a phenyl ring and design of isosteres yielding orally available cathepsin K inhibitors

Journal of Medicinal Chemistry

Volumn 55, Issue 20, 2012, Pages 8827-8837

  Crawford, James J ^a,c   Kenny, Peter W ^a   Bowyer, Jonathan ^a   Cook, Calum R ^a   Finlayson, Jonathan E ^a   Heyes, Christine ^a   Highton, Adrian J ^a   Hudson, Julian A ^a   Jestel, Anja ^b   Krapp, Stephan ^b   Martin, Scott ^a   MacFaul, Philip A ^a   McDermott, Benjamin P ^a   McGuire, Thomas M ^a   Morley, Andrew D ^a   Morris, Jeffrey J ^a   Page, Ken M ^a   Ribeiro, Lyn Rosenbrier ^a   Sawney, Helen ^a   Steinbacher, Stefan ^b   Smith, Caroline ^a   Dossetter, Alexander G ^a   more..

^a ASTRAZENECA   (United Kingdom)

^b PROTEROS BIOSTRUCTURES GMBH   (Germany)

^c GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIMETHOXY PHENYL DERIVATIVE; ANTIRHEUMATIC AGENT; AZD 4996; BALICATIB; CATHEPSIN K INHIBITOR; INDAZOLE DERIVATIVE; ODANACATIB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DESIGN; DRUG IDENTIFICATION; DRUG SELECTIVITY; DRUG STABILITY; DRUG STRUCTURE; HUMAN; MALE; NONHUMAN; RAT; SINGLE DRUG DOSE; SUBSTITUTION REACTION;

ANIMALS; BLOOD PROTEINS; CATHEPSIN K; CELLS, CULTURED; CYCLOHEXANES; DRUG DESIGN; HEPATOCYTES; HUMANS; INDAZOLES; MALE; MODELS, MOLECULAR; PROTEIN BINDING; RATS; RATS, WISTAR; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84867827676     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm301119s     Document Type: Article

References (41)

1. Teitelbaum, S. L. Bone resorption by osteoclasts Science 2000, 289, 1504-1508
2. Lawrence, R. C.; Felson, D. T.; Helmick, C. G.; Arnold, L. M.; Choi, H.; Deyo, R. A.; Gabriel, S.; Hirsch, R.; Hochberg, M. C.; Hunder, G. G.; Jordan, J. M.; Katz, J. N.; Kremers, H. M.; Wolfe, F.; National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 2008, 58, 26-35.
3. Gupta, S.; Singh, R. K.; Dastidar, S.; Ray, A. Cysteine cathepsin S as an immunomodulatory target: present and future trends Expert Opin. Ther. Targets 2008, 12, 291-299
4. Stoch, S. A.; Wagner, J. A. Cathepsin K inhibitors: a novel target for osteoporosis therapy Clin. Pharmacol. Ther. 2008, 83, 172-176
5. Yasuda, Y.; Kaleta, J.; Broemme, D. The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics Adv. Drug Delivery Rev. 2005, 57, 973-993
6. Felson, D. T. Osteoarthritis of the knee N. Engl. J. Med. 2006, 354, 841-848
7. Vasiljeva, O.; Reinheckel, T.; Peters, C.; Turk, D.; Turk, V.; Turk, B. Emerging roles of cysteine cathepsins in disease and their potential as drug targets Curr. Pharm. Des. 2007, 13, 387-403
8. Gauthier, J. Y.; Chauret, N.; Cromlish, W.; Desmarais, S.; Duong, L. T.; Falgueyret, J.; Kimmel, D. B.; Lamontagne, S.; Leger, S.; LeRiche, T.; Li, C. S.; Masse, F.; McKay, D. J.; Nicoll-Griffith, D. A.; Oballa, R. M.; Palmer, J. T.; Percival, M. D.; Riendeau, D.; Robichaud, J.; Rodan, G. A.; Rodan, S. B.; Seto, C.; Therien, M.; Truong, V.; Venuti, M. C.; Wesolowski, G.; Young, R. N.; Zamboni, R.; Black, W. C. The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K Bioorg. Med. Chem. Lett. 2008, 18, 923-928
9. Eisman, J. A.; Bone, H. G.; Hosking, D. J.; McClung, M. R.; Reid, I. R.; Rizzoli, R.; Resch, H.; Verbruggen, N.; Hustad, C. M.; Da, S., Carolyn; Petrovic, R.; Santora, A. C.; Ince, B. A.; Lombardi, A. Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect J. Bone Miner. Res. 2011, 26, 242-251
10. Stoch, S. A.; Zajic, S.; Stone, J.; Miller, D. L.; Van, D., K.; Gutierrez, M. J.; De, D., M.; Liu, L.; Liu, Q.; Scott, B. B.; Panebianco, D.; Jin, B.; Duong, L. T.; Gottesdiener, K.; Wagner, J. A. Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled phase I studies Clin. Pharmacol. Ther. (N. Y., NY, U. S.) 2009, 86, 175-182
11. Update on phase III trial for odanacatib, Mercks investigational Cat-K inhibitor for osteoporosis. Press release, 2012. http://www.merck.com/newsroom/ news-release-archive/research-and-development/2012-0711.html.
12. Dossetter, A. G.; Beeley, H.; Bowyer, J.; Cook, C. R.; Crawford, J. J.; Finlayson, J. E.; Heron, N. M.; Heyes, C.; Highton, A. J.; Hudson, J. A.; Jestel, A.; Kenny, P. W.; Krapp, S.; Martin, S.; MacFaul, P. A.; McGuire, T. M.; Gutierrez, P. M.; Morley, A. D.; Morris, J. J.; Page, K. M.; Ribeiro, L. R.; Sawney, H.; Steinbacher, S.; Smith, C.; Vickers, M. (1 R,2 R)- N -(1-Cyanocyclopropyl)-2-(6-methoxy-1,3,4,5-tetrahydropyrido[4,3- b ]indole-2-carbonyl)cyclohexanecarboxamide (AZD4996): a potent and highly selective cathepsin K inhibitor for the treatment of osteoarthritis J. Med. Chem. 2012, 55, 6363-6374
13. Dossetter, A. G.; Bowyer, J.; Cook, C. R.; Crawford, J. J.; Finlayson, J. E.; Heron, N. M.; Heyes, C.; Highton, A. J.; Hudson, J. A.; Jestel, A.; Krapp, S.; MacFaul, P. A.; McGuire, T. M.; Morley, A. D.; Morris, J. J.; Page, K. M.; Ribeiro, L. R.; Sawney, H.; Steinbacher, S.; Smith, C. Isosteric replacements for benzothiazoles and optimization to potent cathepsin K inhibitors free from hERG channel inhibition Bioorg. Med. Chem. Lett. 2012, 22, 5563-5568
14. Lecaille, F.; Kaleta, J.; Brömme, D. Human and parasitic papain-like cysteine proteases: their role in physiology and pathology and recent developments in inhibitor design Chem. Rev. 2002, 102, 4459-4488
15. Wijkmans, J.; Gossen, J. Inhibitors of cathepsin K: a patent review (2004-2010) Expert Opin. Ther. Pat. 2011, 21, 1611-1629
16. Cai, J.; Jamieson, C.; Moir, J.; Rankovic, Z. Cathepsin K inhibitors, 2000-2004 Expert Opin. Ther. Pat. 2005, 15, 33-48
17. Oballa, R. M.; Truchon, J.; Bayly, C. I.; Chauret, N.; Day, S.; Crane, S.; Berthelette, C. A generally applicable method for assessing the electrophilicity and reactivity of diverse nitrile-containing compounds Bioorg. Med. Chem. Lett. 2007, 17, 998-1002
18. MacFaul, P. A.; Morley, A. D.; Crawford, J. J. A simple in vitro assay for assessing the reactivity of nitrile containing compounds Bioorg. Med. Chem. Lett. 2009, 19, 1136-1138
19. Li, C. S.; Deschenes, D.; Desmarais, S.; Falgueyret, J.; Gauthier, J. Y.; Kimmel, D. B.; Leger, S.; Masse, F.; McGrath, M. E.; McKay, D. J.; Percival, M. D.; Riendeau, D.; Rodan, S. B.; Therien, M.; Truong, V.; Wesolowski, G.; Zamboni, R.; Black, W. C. Identification of a potent and selective non-basic cathepsin K inhibitor Bioorg. Med. Chem. Lett. 2006, 16, 1985-1989
20. Crane, S. N.; Black, W. C.; Palmer, J. T.; Davis, D. E.; Setti, E.; Robichaud, J.; Paquet, J.; Oballa, R. M.; Bayly, C. I.; McKay, D. J.; Somoza, J. R.; Chauret, N.; Seto, C.; Scheigetz, J.; Wesolowski, G.; Masse, F.; Desmarais, S.; Ouellet, M. β-Substituted cyclohexanecarboxamide: a nonpeptidic framework for the design of potent inhibitors of cathepsin K J. Med. Chem. 2006, 49, 1066-1079
21. Falgueyret, J.; Desmarais, S.; Oballa, R.; Black, W. C.; Cromlish, W.; Khougaz, K.; Lamontagne, S.; Masse, F.; Riendeau, D.; Toulmond, S.; Percival, M. D. Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity J. Med. Chem. 2005, 48, 7535-7543
22. Black, W. C.; Percival, M. D. The consequences of lysosomotropism on the design of selective cathepsin K inhibitors ChemBioChem 2006, 7, 1525-1535
23. Luker, T.; Bonnert, R.; Brough, S.; Cook, A. R.; Dickinson, M. R.; Dougall, I.; Logan, C.; Mohammed, R. T.; Paine, S.; Sanganee, H. J.; Sargent, C.; Schmidt, J. A.; Teague, S.; Thom, S. Substituted indole-1-acetic acids as potent and selective CRTh2 antagonists-discovery of AZD1981 Bioorg. Med. Chem. Lett. 2011, 21, 6288-6292
24. Ratcliffe, A. J. Medicinal chemistry strategies to minimize phospholipidosis Curr. Med. Chem. 2009, 16, 2816-2823
25. Organ, M. G.; Abdel-Hadi, M.; Avola, S.; Dubovyk, I.; Hadei, N.; Kantchev, E. A.; OBrien, C. J.; Sayah, M.; Valente, C. Pd-catalyzed aryl amination mediated by well defined, N-heterocyclic carbene (NHC)-Pd precatalysts, PEPPSI Chemistry 2008, 14, 2443-2452
26. Crawford, J. J.; Dossetter, A. G.; Finlayson, J. E.; Heron, N. M. WO2009001127A1, 2008.
27. Dossetter, A. G. A statistical analysis of in vitro human microsomal metabolic stability of small phenyl group substituents, leading to improved design sets for parallel SAR exploration of a chemical series Bioorg. Med. Chem. 2010, 18, 4405-4414
28. Lewis, M. L.; Cucurull-Sanchez, L. Structural pairwise comparisons of HLM stability of phenyl derivatives: Introduction of the Pfizer metabolism index (PMI) and metabolism-lipophilicity efficiency (MLE) J. Comput. -Aided Mol. Des. 2009, 23, 97-103
29. Scott, J. S.; Birch, A. M.; Brocklehurst, K. J.; Broo, A.; Brown, H. S.; Butlin, R. J.; Clarke, D. S.; Davidsson, Ö Ertan, A.; Goldberg, K.; Groombridge, S. D.; Hudson, J. A.; Laber, D.; Leach, A. G.; MacFaul, P. A.; McKerrecher, D.; Pickup, A.; Schofield, P.; Svensson, P. H.; Sörme, P.; Teague, J. Use of small-molecule crystal structures to address solubility in a novel series of G protein coupled receptor 119 agonists: optimization of a lead and in vivo evaluation J. Med. Chem. 2012, 55, 5361-5379
30. Griffen, E.; Leach, A. G.; Robb, G. R.; Warner, D. J. Matched molecular pairs as a medicinal chemistry tool J. Med. Chem. 2011, 54, 7739-7750
31. Testa, B.; Pedretti, A.; Vistoli, G. Reactions and enzymes in the metabolism of drugs and other xenobiotics Drug Discovery Today 2012, 17, 549-560
32. Kalgutkar, A. S.; Nguyen, H. T. Identification of an N-methyl-4- phenylpyridinium-like metabolite of the antidiarrheal agent loperamide in human liver microsomes: underlying reason(s) for the lack of neurotoxicity despite the bioactivation event Drug Metab. Dispos. 2004, 32, 943-952
33. Walsh, J. S.; Miwa, G. T. Bioactivation of drugs: risk and drug design Annu. Rev. Pharmacol. Toxicol. 2011, 51, 145-167
34. Wen, B.; Fitch, W. L. Analytical strategies for the screening and evaluation of chemically reactive drug metabolites Expert Opin. Drug Metab. Toxicol. 2009, 5, 39-55
35. Kalgutkar, A. S.; Vaz, A. D.; Lame, M. E.; Henne, K. R.; Soglia, J.; Zhao, S. X.; Abramov, Y. A.; Lombardo, F.; Collin, C.; Hendsch, Z. S.; Hop, C. E. Bioactivation of the nontricyclic antidepressant nefazodone to a reactive quinone-imine species in human liver microsomes and recombinant cytochrome P450 3A4 Drug Metab. Dispos. 2005, 33, 243-253
36. Kenny, P. W. Hydrogen bonding, electrostatic potential, and molecular design J. Chem. Inf. Model. 2009, 49, 1234-1244
37. Toulmin, A.; Wood, J. M.; Kenny, P. W. Toward prediction of alkane/water partition coefficients J. Med. Chem. 2008, 51, 3720-3730
38. Woods, K. W.; Fischer, J. P.; Claiborne, A.; Li, T.; Thomas, S. A.; Zhu, G.; Diebold, R. B.; Liu, X.; Shi, Y.; Klinghofer, V.; Han, E. K.; Guan, R.; Magnone, S. R.; Johnson, E. F.; Bouska, J. J.; Olson, A. M.; Jong, R. d.; Oltersdorf, T.; Luo, Y.; Rosenberg, S. H.; Giranda, V. L.; Li, Q. Synthesis and SAR of indazole-pyridine based protein kinase B/Akt inhibitors Bioorg. Med. Chem. 2006, 14, 6832-6846
39. Boström, J.; Hogner, A.; Llinàs, A.; Wellner, E.; Plowright, A. T. Oxadiazoles in medicinal chemistry J. Med. Chem. 2012, 55, 1817-1830
40. Becke, A. D. A new mixing of Hartree-Fock and local-density-functional theories J. Chem. Phys. 1993, 98, 1372-1377
41. Lee, C.; Yang, W.; Parr, R. G. Development of the Colle-Salvetti correlation-energy formula into a functional of the electron density Phys. Rev. B: Condens. Matter 1988, 37, 785-789